Agnesian HealthCare urges provider conversations on prostate cancer screenings
A recommendation by the United States Preventive Services Task Force (USPSTF) on prostate cancer screenings differs from other expert groups, including the American Cancer Society, the American Urological Association and providers at Agnesian Cancer Care services.
Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Prior to the use of PSA testing, many prostate cancers were diagnosed when men developed symptoms. These prostate cancer causing symptoms were often aggressive and more advanced, and would lead to suffering and death.
“PSA screening can help with the diagnosis of prostate cancer at an earlier stage where it can be more easily treated,” according to Michael Vander Kooy, MD, a board-certified radiation oncologist with Agnesian Cancer Care services. “Men need to know that not all prostate cancer needs to be treated and that not all men need to be screened.”
However, for patients with those prostate cancer cases that need treatment, early detection with PSA testing helps to provide the best outcomes. The American Cancer Society, the American Urological Association and Agnesian Cancer Care providers believe PSA testing has value in the properly selected patients.
“We believe that all men starting at age 50 (or 45 if there is family history) should discuss testing with their primary care physician or urologist, be given appropriate information about the risks and benefits of PSA testing and prostate cancer treatments, and then make an informed decision if they want testing,” Dr. Vander Kooy says. “Decisions regarding a man’s care should be based on family history, risk factors and other medical factors.”
To learn more, call the Agnesian Cancer Center at (920) 926-4100.